阿奇霉素序贯治疗下呼吸道感染的成本—效果分析

目的:评价阿奇霉素序贯治疗下呼吸道感染的疗效和经济学效果。方法:将180例下呼吸道感染患者随机分为静脉滴注组(59例)、序贯组(62例)、口服组(59例),分别观察其疗效和不良反应,并运用成本-效果分析法进行比较。结果:静脉滴注组、序贯组、口服组的成本分别为296.10、223.30、168.70元,总有效率分别为91.53%、90.32%、67.80%,细菌清除率分别为88.24%、87.04%、66.04%,不良反应发生率分别为5%、5%、0,成本-效果比分别为323.50、247.23、248.82,相对于口服组的增量成本-效果比分别为536.87、242.45。结论:阿奇霉素序贯疗法可有效减缓细菌耐药性的发生,疗效显著且较为经济,为3种治疗方案中的较佳方案。

Cost-effectiveness Analyses of Sequential Therapy with Azithromycin for Lower Respiratory Tract Infection

OBJECTIVE：To evaluate the curative effect and cost of sequential therapy with azithromycin for Lower respiratory tract infection. METHODS：A total of 180 patients with lower respiratory tract infection were randomly divided into intravenous therapy group（59 cases）, sequential therapy group（62 cases）,and p.o. group（59 cases）. The therapeutic effects and the adverse drug reactions of the 3 groups were observed, and the data was subjected to cost-effective analysis in pharmacoeconomics. RESULTS：In intravenous therapy group, sequential therapy group, and p.o. group, the costs were 296.10, 223.30 and 168.70 yuan, respectively. The clinical effective rates were 91.53%, 90.32%, and 67.80%, respectively. The total bacterial eradication rates were 88.24%, 87.04%, and 66.04%, respectively. The rates of adverse drug reactions were 5%, 5%, and 0, respectively. The cost-effectiveness were 323.50, 247.23, and 248.82, respectively, and the incremental cost-effective ratios in the intravenous therapy group and sequential therapy group were 536.87 and 242.45, respectively as against p.o. group. CONCLUSION： Among the 3 schemes, sequential therapy with azithromycin with high efficiency and economy is the optimal one, which can reduce bacterial resistance.